SNG vs. TRX, COS, C4XD, DDDD, FUM, OKYO, AOR, SAR, OPTI, and AREC
Should you be buying Synairgen stock or one of its competitors? The main competitors of Synairgen include Tissue Regenix Group (TRX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Futura Medical (FUM), OKYO Pharma (OKYO), AorTech International (AOR), Sareum (SAR), OptiBiotix Health (OPTI), and Arecor Therapeutics (AREC). These companies are all part of the "biotechnology" industry.
Synairgen vs.
Synairgen (LON:SNG) and Tissue Regenix Group (LON:TRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability.
Synairgen has a net margin of 0.00% compared to Tissue Regenix Group's net margin of -3.46%. Tissue Regenix Group's return on equity of -2.87% beat Synairgen's return on equity.
Tissue Regenix Group received 9 more outperform votes than Synairgen when rated by MarketBeat users. Likewise, 69.53% of users gave Tissue Regenix Group an outperform vote while only 56.46% of users gave Synairgen an outperform vote.
Tissue Regenix Group has higher revenue and earnings than Synairgen. Tissue Regenix Group is trading at a lower price-to-earnings ratio than Synairgen, indicating that it is currently the more affordable of the two stocks.
Synairgen has a beta of -2.23, suggesting that its stock price is 323% less volatile than the S&P 500. Comparatively, Tissue Regenix Group has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.
In the previous week, Synairgen's average media sentiment score of 0.00 equaled Tissue Regenix Group'saverage media sentiment score.
30.7% of Synairgen shares are owned by institutional investors. Comparatively, 37.0% of Tissue Regenix Group shares are owned by institutional investors. 3.2% of Synairgen shares are owned by company insiders. Comparatively, 47.3% of Tissue Regenix Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Tissue Regenix Group beats Synairgen on 10 of the 12 factors compared between the two stocks.
Get Synairgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNG and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synairgen Competitors List
Related Companies and Tools
This page (LON:SNG) was last updated on 5/1/2025 by MarketBeat.com Staff
